会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 103. 发明申请
    • Functionalized polymers and their biomedical and pharmaceutical uses
    • 功能化聚合物及其生物医药和药物用途
    • US20050203270A1
    • 2005-09-15
    • US10510407
    • 2003-04-03
    • Patrice HildgenGregoire LeclairRichard Quesnel
    • Patrice HildgenGregoire LeclairRichard Quesnel
    • A61K9/16C08G63/08C08G63/91C08G65/22C08L71/02
    • C08G65/22A61K9/1647C08G63/912C08L71/02C08L2203/02C08L2205/05C08L2666/18
    • Disclosed is a polymer of the formula I: wherein: Z is —O— or —NH—; R1 represents a non-functional backbone of a hydroxy acid or amino acid derived from a cyclic ester or diester or cyclic amide or diamide monomer (A); R2 represents a non-functional chain derived from an epoxide monomer (B), said chain ending with a graftable hydroxy or carboxylic group; n is the number of units derived from the monomers (A); m is the number of units derived from the monomers (B); and x is equal to n+m, the ratio m/x ranging from 0.005 to 0.30. Also disclosed is a process of preparing this functionalizable polymer to the hydroxy or carboxylic groups of which can be grafted a compound selected from the group consisting of: ligands specific to cellular receptors, such as Selectine E; lipids; peptides; polyethers; polyacrylates; natural polymers; polyosides; antigens or antibodies; salen; and cyclodextrins. The so grafted polymer can be used as carried or excipient in the biomedical and pharmaceutical fields.
    • 公开了式I的聚合物:其中:Z是-O-或-NH-; R 1代表衍生自环酯或二酯或环酰胺或二酰胺单体(A)的羟基酸或氨基酸的非官能主链; R 2表示衍生自环氧化物单体(B)的非官能链,所述链以可接枝的羟基或羧基为末端; n是衍生自单体(A)的单元数; m是衍生自单体(B)的单元数; x等于n + m,m / x的比例范围为0.005〜0.30。 还公开了将该可官能化聚合物制备成羟基或羧基的方法,其可以接枝选自以下的化合物:对细胞受体特异性的配体,例如Selectine E; 脂质 肽类 聚醚 聚丙烯酸酯; 天然聚合物; 多糖苷 抗原或抗体; 萨伦 和环糊精。 所述接枝聚合物可用作生物医药领域的载体或赋形剂。
    • 104. 发明申请
    • Bioadhesive polymers with catechol functionality
    • 具有儿茶酚功能的生物粘合剂聚合物
    • US20050201974A1
    • 2005-09-15
    • US11009327
    • 2004-12-09
    • Marcus SchestopolJules JacobRyan DonnellyThomas RickettsAvinash NangiaEdith MathiowitzZe'ev Shaked
    • Marcus SchestopolJules JacobRyan DonnellyThomas RickettsAvinash NangiaEdith MathiowitzZe'ev Shaked
    • A61K9/00A61K9/20A61K31/74C08F8/32C08G63/91C09J135/00C09J167/00C09J167/04C09J201/06
    • C08F8/32A61K9/0004A61K9/006A61K9/0065A61K9/204A61K9/2077A61K9/2081A61K9/2086C08G63/91C08G63/912C09J167/00C09J167/04C08F222/06
    • Polymers with improved bioadhesive properties and methods for improving bioadhesion of polymers have been developed. A compound containing an aromatic group which contains one or more hydroxyl groups is grafted onto a polymer or coupled to individual monomers. In one embodiment, the polymer is a biodegradable polymer. In another embodiment, the monomers may be polymerized to form any type of polymer, including biodegradable and non-biodegradable polymers. In some embodiments, the polymer is a hydrophobic polymer. In the preferred embodiment, the aromatic compound is catechol or a derivative thereof and the polymer contains reactive functional groups. In the most preferred embodiment, the polymer is a polyanhydride and the aromatic compound is the catechol derivative, DOPA. These materials display bioadhesive properties superior to conventional bioadhesives used in therapeutic and diagnostic applications. These bioadhesive materials can be used to fabricate new drug delivery or diagnostic systems with increased residence time at tissue surfaces, and consequently increase the bioavailability of a drug or a diagnostic agent. In a preferred embodiment, the bioadhesive material is a coating on a controlled release oral dosage formulation and/or forms a matrix in an oral dosage formulation.
    • 已经开发了具有改进的生物粘附性质的聚合物和改善聚合物生物粘附的方法。 含有含有一个或多个羟基的芳族基团的化合物被接枝到聚合物上或与单独的单体偶联。 在一个实施方案中,聚合物是可生物降解的聚合物。 在另一个实施方案中,单体可以聚合以形成任何类型的聚合物,包括可生物降解和不可生物降解的聚合物。 在一些实施方案中,聚合物是疏水性聚合物。 在优选的实施方案中,芳族化合物是儿茶酚或其衍生物,并且聚合物含有反应性官能团。 在最优选的实施方案中,聚合物是聚酐,芳族化合物是邻苯二酚衍生物DOPA。 这些材料显示出比用于治疗和诊断应用的常规生物粘合剂优越的生物粘附性。 这些生物粘附材料可用于制造具有增加的组织表面停留时间的新药物递送或诊断系统,并因此提高药物或诊断剂的生物利用度。 在优选的实施方案中,生物粘附材料是在控释口服剂量制剂上的涂层和/或在口服剂量制剂中形成基质。
    • 108. 发明授权
    • Polyhydroxyalkanoate compositions having controlled degradation rates
    • 具有受控降解速率的聚羟基链烷酸酯组合物
    • US06867248B1
    • 2005-03-15
    • US10403244
    • 2003-03-28
    • David P. MartinFrank SkralySimon F. Williams
    • David P. MartinFrank SkralySimon F. Williams
    • A61K9/16A61K47/48A61L15/26A61L17/10A61L17/12A61L24/00A61L26/00A61L27/18A61L27/34A61L27/58A61L29/06A61L31/06A61L31/14C08G63/06C08G63/64C08G63/685C08G63/688C08G63/91C08K5/00C12N5/00C12P7/62C08L67/04
    • C12P7/625A61K9/1647A61K47/593A61K47/6957A61L15/26A61L17/10A61L17/12A61L24/0042A61L26/0019A61L26/009A61L27/18A61L27/34A61L27/58A61L29/06A61L31/06A61L31/148C08G63/06C08G63/64C08G63/6852C08G63/6882C08G63/912C08K5/0033C12N5/0068C12N2533/30C08L67/04
    • Biocompatible polyhydroxyalkanoate compositions with controlled degradation rates have been developed. In one embodiment, the polyhydroxyalkanoates contain additives to alter the degradation rates. In another embodiment, the polyhydroxyalkanoates are formed of mixtures of monomers or include pendant groups or modifications in their backbones to alter their degradation rates. In still another embodiment, the polyhydroxyalkanoates are chemically modified. Methods for manufacturing the devices which increase porosity or exposed surface area can be used to alter degradability. For example, as demonstrated by the examples, porous polyhydroxyalkanoates can be made using methods that creates pores, voids, or interstitial spacing, such as an emulsion or spray drying technique, or which incorporate leachable or lyophilizable particles within the polymer. Examples describe poly(4HB) compositions including foams, coatings, meshes, and microparticles. As demonstrated by the examples, these polyhydroxyalkanoate compositions have extremely favorable mechanical properties, as well as are biocompatible and degrade within desirable time frames under physiological conditions. These polyhydroxyalkanoate materials provide a wider range of polyhydroxyalkanoate degradation rates than are currently available. Methods for processing these materials, particularly for therapeutic, prophylactic or diagnostic applications, or into devices which can be implanted or injected, are also described.
    • 已经开发了具有受控降解速率的生物相容性聚羟基链烷酸酯组合物。 在一个实施方案中,聚羟基链烷酸酯含有改变降解速率的添加剂。 在另一个实施方案中,聚羟基链烷酸酯由单体的混合物形成或包括侧链基团或其主链中的修饰以改变其降解速率。 在另一个实施方案中,聚羟基链烷酸酯被化学改性。 用于制造增加孔隙率或暴露表面积的装置的方法可用于改变降解性。 例如,如通过实施例所证明的,多孔聚羟基链烷酸酯可以使用产生孔,空隙或间隙的方法,例如乳液或喷雾干燥技术,或者在聚合物内含有可浸出或可冷冻干燥的颗粒。 实例描述了包括泡沫,涂层,网格和微粒的聚(4HB)组合物。 如实施例所示,这些聚羟基链烷酸酯组合物在生理条件下在期望的时间范围内具有非常有利的机械性能以及生物相容性和降解性。 这些聚羟基链烷酸酯材料提供比目前可获得的更广泛的聚羟基链烷酸酯降解速率。 还描述了用于处理这些材料的方法,特别是用于治疗,预防或诊断应用,或可植入或注射的装置。